FibroGen (MEX:FGEN) Interest Expense : MXN-156.2 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is FibroGen Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. FibroGen's interest expense for the three months ended in Dec. 2024 was MXN 136.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-156.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. FibroGen's Operating Income for the three months ended in Dec. 2024 was MXN -1,892.8 Mil. FibroGen's Interest Expense for the three months ended in Dec. 2024 was MXN 136.1 Mil. FibroGen did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

FibroGen Interest Expense Historical Data

The historical data trend for FibroGen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Interest Expense Chart

FibroGen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-47.78

-44.17

-28.07

-137.41

-172.00

FibroGen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															40.21	-82.92	-111.09	-98.33	136.13

FibroGen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-156.2 Mil.

FibroGen (MEX:FGEN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

FibroGen's Interest Expense for the three months ended in Dec. 2024 was MXN136.1 Mil. Its Operating Income for the three months ended in Dec. 2024 was MXN-1,892.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was MXN1,524.4 Mil.

FibroGen's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

The higher the ratio, the stronger the company's financial strength is.

FibroGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FGEN:USA 0IL8:UK 1FG:Germany 1FG:Germany

Address

350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.